European Commission Approves AbbVie's Elahere for Platinum-Resistant Ovarian Cancer
Key Insights
The European Commission has approved AbbVie (search)'s Elahere (mirvetuximab soravtansine) for treating folate receptor-alpha (search) (FRα) positive, platinum-resistant ovarian cancer (search).
Elahere is the first and only FRα-directed antibody-drug conjugate approved in the EU, Iceland, Liechtenstein, Norway, and Northern Ireland.
The approval covers patients who have received one to three prior systemic treatment regimens for high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
AbbVie (search)'s Elahere (mirvetuximab soravtansine) has received approval from the European Commission for the treatment of adult patients with folate receptor-alpha (search) (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. These patients must have already undergone one to three prior systemic treatment regimens.
Elahere marks a significant advancement as the first and only folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland. This approval provides a new targeted treatment option for patients with limited alternatives.
Mirvetuximab soravtansine, marketed under the brand name Elahere, was granted approval by the European Commission in November 2024. It previously received full FDA approval in the United States in March 2024, highlighting its growing recognition as an effective treatment. Marketing authorization submissions for mirvetuximab soravtansine are currently under review in multiple other countries, suggesting a potential expansion of its availability worldwide.
The approval underscores the importance of targeting FRα in ovarian cancer (search), offering a novel approach to combatting this challenging disease. The antibody-drug conjugate mechanism allows for precise delivery of cytotoxic agents to cancer cells expressing FRα, potentially improving efficacy and reducing off-target effects.